<DOC>
	<DOCNO>NCT03103451</DOCNO>
	<brief_summary>This open label , phase 1 , `` 3+3 '' , placebo-controlled dose escalate study tolerability , safety , pharmacokinetics , pharmacodynamics immunogenicity single subcutaneous injection novel monoclonal bispecific antibody human IL-17/TNFa . The study enroll 28 healthy male volunteer .</brief_summary>
	<brief_title>First-in-human Study Evaluate Safety , Tolerability , Pharmacokinetics Pharmacodynamics Various Doses BCD-121 Healthy Subjects</brief_title>
	<detailed_description>Simultaneous blockade IL-17 TNFa potential therapeutic way treatment several autoimmune disorder . BCD-121 novel humanize monoclonal bispecific antibody human IL17 TNFa develop JCS BIOCAD ( Russia ) first step clinical evaluation . BCD-121-1 study first-in-human clinical trial intend evaluate tolerability , safety , pharmacokinetics , pharmacodynamics immunogenicity BCD-121 use single step-by-step escalate subcutaneous dose healthy male volunteer . During study expect determine diapason safety dose BCD-121 ( incl . MTD ) thereafter evaluate phase 2 study .</detailed_description>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>sing informed consent male gender 1845 year age inclusively BMI between18.530.0 kg/sq.m . absence sings hepatic , renal , gastrointestinal , cardiovascular , endocrine , respiratory , immunologic , hematologic , dermatologic , neurologic abnormality screen or/and anamnesis parameter complete blood count , blood biochemistry , urinalysis exceed reference value , use Study site laboratory normal hemodynamic parameter absence chronic infection ( HIV , syphilis , hepatitis ะ ะก , tuberculosis ) chronic inflammation absence infection within 4 week randomization absence mental disorder condition ( incl . depression ) , may affect ability participant follow Protocol health wellbeing ( volunteer 's opining opinion ) least 30 day randomization . absence alcohol drug addiction sign ( incl . history addiction ) volunteer 's ability follow Protocol procedure consent volunteer sexual partner childbearing potential use adequate contraception history use monoclonal antibody IL17 TNFa know severe allergy ( anaphylaxis multidrug intolerance ) know intolerance medicine contain monoclonal antibody ( murine , humanize , human ) excipients BCD121/placebo major surgery within 30 day prior screen severe infection ( require hospitalization , parenteral use antimicrobial agent ) systemic use antimicrobial 4 episode respiratory tract infection within 6 month prior screen presence disorder may affect pharmacokinetics BCD121 history fever equal exceed 40 degree Celsius history hepatic transaminase increase 2.5 x ULN history seizure actual prior depression , suicidal tendency use medicine , vitamin , biologically active additive within 14 day prior date BCD085 injection use medicine affect hemodynamics hepatic function within 30 day prior date BCD121 injection simultaneous participation clinical trial , well former participation clinical trial within 3 month study initiation . previous participation study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>